DADouglas Arneson

Douglas Arneson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Douglas Arneson has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HIV-SEQ Reveals Global Host Gene Expression Differences Between HIV-Transcribing Cells from Viremic and Suppressed People with HIV

    by Julie Frouard, Sushama Telwatte, Xiaoyu Luo, Natalie Elphick, Reuben Thomas, Douglas Arneson, Pavitra Roychoudhury, Atul J Butte, Joseph K Wong, Rebecca Hoh, et al.

    “Active” reservoir cells transcribing HIV can perpetuate chronic inflammation in virally suppressed people with HIV (PWH) and likely contribute to viral rebound after antiretroviral therapy (ART) interruption, so they represent an important target for new therapies. These cells, however, are difficult to study using single-cell RNA-seq (scRNA-seq) due to their low frequency and low levels of HIV transcripts, which are usually not polyadenylated. Here, we developed “HIV-seq” to enable more efficient capture of HIV transcripts – including non-polyadenylated ones – for scRNA-seq analysis of cells from PWH. By spiking in a set of custom-designed capture sequences targeting conserved regions of the HIV genome during scRNA-seq, we increased our ability to find HIV RNA+ cells from PWH by up to 44%. Implementing HIV-seq in conjunction with surface phenotyping by CITE-seq on paired blood specimens from PWH before vs. after ART suppression, we found that HIV RNA+ cells were enriched among T effector memory (Tem) cells during both viremia and ART suppression, but exhibited a cytotoxic signature during viremia only. By contrast, HIV RNA+ cells from the ART-suppressed timepoints exhibited a distinct anti-inflammatory signature involving elevated TGF-β and diminished IFN signaling. Overall, these findings demonstrate that active reservoir cells exhibit transcriptional features distinct from HIV RNA+ cells during viremia, and underscore HIV-seq as a useful tool to better understand the mechanisms by which HIV-transcribing cells can persist during ART.


  • Open Access

    Personalizing treatment selection in Crohn’s disease: a meta-analysis of individual participant data from fifteen randomized controlled trials

    by Vivek A. Rudrapatna, Vignesh G. Ravindranath, Douglas V. Arneson, Arman Mosenia, Atul J. Butte, Shan Wang

    BACKGROUND Meta-analyses have found anti-TNF drugs to be the best treatment, on average, for Crohn’s disease. We performed a subgroup analysis to determine if it is possible to achieve more efficacious outcomes by individualizing treatment selection. METHODS We obtained participant-level data from 15 trials of FDA-approved treatments (N=5703). We used sequential regression and simulation to model week six disease activity as a function of drug class, demographics, and disease-related features. We performed hypothesis testing to define subgroups based on rank-ordered preferences for treatments. We queried health records from University of California Health (UCH) to estimate the impacts these models could have on practice. We computed the sample size needed to prospectively test a prediction of our models. RESULTS 45% of the participants (N=2561) showed greater efficacy with at least one drug class (anti-TNF, anti-IL-12/23, anti-integrin) over another. They were classifiable into 6 subgroups, two showing greatest efficacy with anti-TNFs (36%, N=2064). Women over 50 showed superior responses with anti-IL-12/23s. Although they represented only 2% of the trial-based cohort, 25% of Crohn’s patients at UCH are women over 50 (N=5,647), consistent with potential selection bias in trials. Moreover, 75% of biologic-exposed women over 50 did not receive an anti-IL12/23 first-line, supporting the potential value of these models. A future trial with 250 patients per arm will have 97% power to confirm the superiority of anti-IL-12/23s over anti-TNFs in these patients. A treatment recommendation tool is available at https://crohnsrx.org. CONCLUSIONS Personalizing treatment can improve outcomes in Crohn’s disease. Future work is needed to confirm these findings, and improve representativeness in Crohn’s trials. BACKGROUND AND CONTEXT Patients with Crohn’s disease likely harbor different underlying susceptibilities to different treatments. Yet, clinical practice today is guided by cohort-averaging studies that ignore patient-level variation. Personalized treatment strategies are needed. NEW FINDINGS We re-analyzed data from 15 trials to model individual outcomes to different treatments. We found 6 subgroups, including women over 50 whose superior responses to anti-IL-12/23s deviate from the majority trend. LIMITATIONS This was a meta-analysis of trial data; confirmatory prospective studies are needed. Our models need to be updated to include recently approved treatments. CLINICAL RESEACH RELEVANCE Our findings confirm that heterogeneity of treatment effect does exist in Crohn’s disease. A future trial with 250 patients per arm is 97% powered to show that anti-IL-12/23s are more efficacious than anti-TNFs in women over 50. Incidentally, we also found evidence of possible selection bias into Crohn’s trials. Future work is needed to study and rectify this. BASIC RESEARCH RELEVANCE We found that patients do in fact harbor different underlying susceptibilities to different treatment mechanisms of action. But the biological basis of this is unknown. Future studies designed to elucidate this may reveal new therapeutic targets in Crohn’s disease.


  • Open Access

    Systems spatiotemporal dynamics of traumatic brain injury at single-cell resolution reveals humanin as a therapeutic target

    by Douglas Arneson, Guanglin Zhang, In Sook Ahn, Zhe Ying, Graciel Diamante, Ingrid Cely, Victoria Palafox-Sanchez, Fernando Gomez-Pinilla, Xia Yang

    Background: The etiology of mild traumatic brain injury (mTBI) remains elusive due to the tissue and cellular heterogeneity of the affected brain regions that underlie cognitive impairments and subsequent neurological disorders. This complexity is further exacerbated by disrupted circuits within and between cell populations across brain regions and the periphery, which occur at different timescales and in spatial domains.Methods: We profiled three tissues (hippocampus, frontal cortex, and blood leukocytes) at the acute (24-h) and subacute (7-day) phases of mTBI at single-cell resolution.Results: We demonstrated that the coordinated gene expression patterns across cell types were disrupted and re-organized by TBI at different timescales with distinct regional and cellular patterns. Gene expression-based network modeling implied astrocytes as a key regulator of the cell–cell coordination following mTBI in both hippocampus and frontal cortex across timepoints, andmt-Rnr2, which encodes the mitochondrial peptide humanin, as a potential target for intervention based on its broad regional and dynamic dysregulation following mTBI. Treatment of a murine mTBI model with humanin reversed cognitive impairment caused by mTBI through the restoration of metabolic pathways within astrocytes.Conclusions: Our results offer a systems-level understanding of the dynamic and spatial regulation of gene programs by mTBI and pinpoint key target genes, pathways, and cell circuits that are amenable to therapeutics.


  • Open Access

    Open challenges in developing digital therapeutics in the United States

    by Brenda Y Miao, Douglas Arneson, Michelle Wang, Atul J Butte


  • Open Access

    CovidCounties is an interactive real time tracker of the COVID19 pandemic at the level of US counties

    by Douglas Arneson, Matthew Elliott, Arman Mosenia, Boris Oskotsky, Samuel Solodar, Rohit Vashisht, Travis Zack, Paul Bleicher, Atul J. Butte, Vivek A. Rudrapatna

    Management of the COVID-19 pandemic has proven to be a significant challenge to policy makers. This is in large part due to uneven reporting and the absence of open-access visualization tools to present local trends and infer healthcare needs. Here we report the development of CovidCounties.org, an interactive web application that depicts daily disease trends at the level of US counties using time series plots and maps. This application is accompanied by a manually curated dataset that catalogs all major public policy actions made at the state-level, as well as technical validation of the primary data. Finally, the underlying code for the site is also provided as open source, enabling others to validate and learn from this work.


  • Open Access

    MethylResolver—a method for deconvoluting bulk DNA methylation profiles into known and unknown cell contents

    by Douglas Arneson, Xia Yang, Kai Wang

    Bulk tissue DNA methylation profiling has been used to examine epigenetic mechanisms and biomarkers of complex diseases such as cancer. However, heterogeneity of cellular content in tissues complicates result interpretation and utility. In silico deconvolution of cellular fractions from bulk tissue data offers a fast and inexpensive alternative to experimentally measuring such fractions. In this study, we report the design, implementation, and benchmarking of MethylResolver, a Least Trimmed Squares regression-based method for inferring leukocyte subset fractions from methylation profiles of tumor admixtures. Compared to previous approaches MethylResolver is more accurate as unknown cellular content in the mixture increases and is able to resolve tumor purity-scaled immune cell-type fractions without a cancer-specific signature. We also present a pan-cancer deconvolution of TCGA, recapitulating that high eosinophil fraction predicts improved cervical carcinoma survival and identifying elevated B cell fraction as a previously unreported predictor of poor survival for papillary renal cell carcinoma.


  • Open Access

    CovidCounties - an interactive, real-time tracker of the COVID-19 pandemic at the level of US counties

    by Douglas Arneson, Matthew Elliott, Arman Mosenia, Boris Oskotsky, Rohit Vashisht, Travis Zack, Paul Bleicher, Atul J. Butte, Vivek A. Rudrapatna

    Management of the COVID-19 pandemic has proven to be a significant challenge to policy makers. This is in large part due to uneven reporting and the absence of open-access visualization tools to present local trends and infer healthcare needs. Here we report the development of CovidCounties.org, an interactive web application that depicts daily disease trends at the level of US counties using time series plots and maps. This application is accompanied by a manually curated dataset that catalogs all major public policy actions made at the state-level, as well as technical validation of the primary data. Finally, the underlying code for the site is also provided as open source, enabling others to validate and learn from this work.


  • Open Access

    Integrative Single-Cell Omics to Uncover Mechanistic Insights and Drug Repurposing Candidates for Pulmonary Arterial Hypertension

    by J. Hong, D. Arneson, S. Umar, G. Ruffenach, I.S. Ahn, G. Diamente, M. Bhetraratana, C. Cunningham, M. Eghbali, X. Yang

  • Hypothalamic oestrogen receptor alpha establishes a sexually dimorphic regulatory node of energy expenditure

    by J. Edward van Veen, Laura G. Kammel, Patricia C. Bunda, Michael Shum, Michelle S. Reid, Megan G. Massa, Douglas V. Arneson, Jae W. Park, Zhi Zhang, Alexia M. Joseph, et al.

    Oestrogen receptor alpha (ERα) signalling in the ventromedial hypothalamus (VMH) contributes to energy homeostasis by modulating physical activity and thermogenesis. However, the precise neuronal populations involved remain undefined. Here, we describe six neuronal populations in the mouse VMH by using single-cell RNA transcriptomics and in situ hybridization. ERα is enriched in populations showing sex-biased expression of reprimo (Rprm), tachykinin 1 (Tac1) and prodynorphin (Pdyn). Female-biased expression of Tac1 and Rprm is patterned by ERα-dependent repression during male development, whereas male-biased expression of Pdyn is maintained by circulating testicular hormone in adulthood. Chemogenetic activation of ERα-positive VMH neurons stimulates heat generation and movement in both sexes. However, silencing Rprm gene function increases core temperature selectively in females and ectopic Rprm expression in males is associated with reduced core temperature. Together, these findings reveal a role for Rprm in temperature regulation and ERα in the masculinization of neuron populations that underlie energy expenditure.


  • Open Access

    PharmOmics: A Species- and Tissue-specific Drug Signature Database and Online Tool for Drug Repurposing

    by Yen-Wei Chen, Graciel Diamante, Jessica Ding, Thien Xuan Nghiem, Jessica Yang, Sung-Min Ha, Peter Cohn, Douglas Arneson, Montgomery Blencowe, Jennifer Garcia, et al.

    Drug development has been hampered by a high failure rate in clinical trials due to efficacy or safety issues not predicted by preclinical studies in model systems. A key contributor is our incomplete understanding of drug functions across organ systems and species. Therefore, elucidating species- and tissue-specific actions of drugs can provide systems level insights into therapeutic efficacy, potential adverse effects, and interspecies differences that are necessary for more effective translational medicine. Here, we present a comprehensive drug knowledgebase and analytical tool, PharmOmics, comprised of genomic footprints of drugs in individual tissues from human, mouse, and rat transcriptome data from GEO, ArrayExpress, TG-GATEs, and DrugMatrix. Using multi-species and multi-tissue gene expression signatures as molecular indicators of drug functions, we developed gene network-based approaches for drug repositioning. We demonstrate the potential of PharmOmics to predict drugs for new disease indications and validated two predicted drugs for non-alcoholic fatty liver disease in mice. We also examined the potential of PharmOmics to identify drugs related to hepatoxicity and nephrotoxicity. By combining tissue- and species-specific in vivo drug signatures with biological networks, PharmOmics serves as a complementary tool to support drug characterization.